Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9345377 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL22647718 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL3018392 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL22647791 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL22607980 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL521587 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL919347 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL6562247 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL22647724 | 1.00 | TSHR (0.70) | TSHRNAAAEPHX1RAD52NPSR1 | |
| SCHEMBL27640559 | 0.98 | TSHR (0.68) | TSHRNAAAEPHX1RAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | claimed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | claimed |
| US-20260076935-A1 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2026-03-19 | — | — | US | disclosed |
| EP-4683625-A2 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | The Trustees Of Columbia University In The City Of New York (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025058667-A2 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4329743-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | Birkenmeier, Gerd (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-20230044979-A1 | ANIMAL CELL CULTURING METHOD | AJINOMOTO CO., INC. (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4123013-A1 | ANIMAL CELL CULTURING METHOD | AJINOMOTO CO., INC. (JP) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022228652-A1 | MEANS AND METHOD FOR TREATING VIRAL INFECTIONS | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022228651-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| CN-115279893-A | Method for culturing animal cells | 味之素株式会社 | 2022-11-01 | — | — | CN | disclosed |
| EP-1877141-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1874407-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-7230062-B2 | Acrylic copolymer | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2007-06-12 | — | — | US | disclosed |
| WO-2006108681-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108682-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108680-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST PROTOZOA AND HELMINTHES | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108679-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE TO COMBAT CANCER | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| US-20050182224-A1 | Acrylic copolymer | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2005-08-18 | — | — | US | disclosed |
| US-4006132-A | 1'-Formyl-1'-halobenzeneazomethane compounds having herbicidal activity | THE UPJOHN COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076935-A1 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | PC, PDK1, PDK4 | TSHR 2677/4885NAAA 4242/4885EPHX1 151/4885 |
| US-20230044979-A1 | ANIMAL CELL CULTURING METHOD | NPEPPS, ZDHHC2, EIF2A | TSHR 1782/4885NAAA 2205/4885EPHX1 2323/4885 |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | MPO, BDNF, NLN | TSHR 4770/4885NAAA 1869/4885EPHX1 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.